The influence of genetic variations of human organic anion transporting polypeptides in drug disposition
The research in our group is aimed to understand the influence of natural variations of human transporter genes on drug performance, which will largely impact on the therapeutic outcome of the disease treatment.
Human organic anion transporting polypeptides (OATPs) are important transporters that modulate the cellular influx of endogenous substances and many clinically important drugs. OATP dysfunction may have serious consequences for human health by altering homeostasis and impairing drug efficacy and disposition. It has been proved that OATPs can interact with many anti-cancer agents. We recently identified several novel variants of a particular OATP protein in cancer patients who received an anti-cancer agent. It is also know that the OATP protein that we are interested with is responsible for the cellular uptake of this agent. The present project will evaluate the underlying molecular mechanisms whereby these genetic variations impact on transporter function. This study will build on our previous findings to define the mechanisms that human genetic variations influence transporter function, therefore, impact on the outcome of drug therapy. This pharmacogenomic information could then be utilised to tailor the selection of drug and its dosage to the individual in the future.
The techniques involved in this project include:
Gene Cloning and site-directed mutagenesis
Plasmid/genomic DNA preparation
Cell culturing techniques including gene transfection
Want to find out more?
The opportunity ID for this research opportunity is: 1574
Other opportunities with Professor Michael Murray